Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) have earned an average broker rating score of 2.00 (Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company. Harvard Bioscience’s rating score has declined by 100% from 90 days ago as a result of a number of analysts’ upgrades and downgrades.
Brokers have set a twelve-month consensus price objective of $2.50 for the company and are forecasting that the company will post $0.04 earnings per share for the current quarter, according to Zacks. Zacks has also given Harvard Bioscience an industry rank of 62 out of 256 based on the ratings given to related companies.
Several equities analysts recently weighed in on the company. Janney Montgomery Scott downgraded Harvard Bioscience from a “buy” rating to a “neutral” rating and set a $2.00 target price on the stock. in a research report on Monday, July 8th. Benchmark reiterated a “buy” rating on shares of Harvard Bioscience in a research report on Friday, July 19th. ValuEngine upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Zacks Investment Research downgraded Capital Senior Living from a “buy” rating to a “hold” rating in a research report on Tuesday.
Shares of NASDAQ:HBIO traded up $0.04 during trading on Tuesday, hitting $2.53. The stock had a trading volume of 346,467 shares, compared to its average volume of 319,119. Harvard Bioscience has a 12 month low of $1.51 and a 12 month high of $6.70. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.22 and a quick ratio of 1.12. The company has a market cap of $95.35 million, a P/E ratio of 16.87 and a beta of 1.49. The company has a fifty day moving average of $2.02.
Harvard Bioscience (NASDAQ:HBIO) last posted its earnings results on Thursday, July 25th. The medical instruments supplier reported $0.03 EPS for the quarter, topping the Zacks’ consensus estimate of $0.02 by $0.01. The business had revenue of $29.58 million during the quarter, compared to analyst estimates of $29.30 million. Harvard Bioscience had a positive return on equity of 5.22% and a negative net margin of 0.46%. As a group, equities analysts expect that Harvard Bioscience will post 0.09 earnings per share for the current fiscal year.
About Harvard Bioscience
Harvard Bioscience, Inc provides scientific instruments, systems, software, and services used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, sample preparation plates and columns, and electroporation and electrofusion instruments under the Biochrom, BioDrop, Hoefer, Scie-plas, QuikPrep, and BTX brands.
Recommended Story: Momentum Indicator: Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.